You just read:

XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome

News provided by

XTL Biopharmaceuticals Ltd

Jan 05, 2017, 08:30 ET